Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

Hughes, Richard; Donofrio, Peter D.; Bril, Vera; Dalakas, Marinos C.; Deng, Chunqin; Kim, Hanna; Hartung, Hans‐Peter; Latov, Norman; Merkies, Ingemar S. J.; Doorn, Pieter A. van

doi:10.1016/s1474-4422(07)70329-0

Cited by 585 publications

(690 citation statements)

References 23 publications

Supporting

Mentioning

643

Contrasting

Unclassified

Order By: Relevance

“…In the ICE study [47], 10 % IVIG [10 % caprylatechromatography purified immune globulin (IGIV-C)] efficacy and safety has been studied in 117 patients with CIDP enrolled in a randomized, double-blind, placebo-controlled, responseconditional crossover trial. IGIV-C or placebo was given at the initial dose of 2 g/kg, then 1 g/kg every 3 weeks for up to 24 weeks.…”

Section: Ivigmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

Section: Ivigmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…In our experience (MCD), cranial neuropathies such as Bell's palsy or trigeminal neuralgia are not infrequently seen with all systemic rheumatic diseases. Steroids, alone or combined with IVIg, or plasmapheresis are the best treatment options for CIDP (grade 1A) [37,38]. IV cyclophosphamide is the preferable treatment in vasculitic neuropathy (grade 1A) [22,39,40].…”

Section: Peripheral Neuropathiesmentioning

confidence: 99%

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

et al. 2016

View full text Add to dashboard Cite

Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example antitumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients.

show abstract

“…A recent randomized, double-blind, placebo-controlled, response-conditional cross-over trial included 117 patients with CIDP (ICE trail). The long-term efficacy of IVIG (baseline loading dose of 2 g/kg over 2-4 days and then a maintenance dose of 1 g/kg over 1-2 days every 3 weeks for up to 24 weeks) was compared with placebo [36]. IVIG or placebo was administered for up to 24 weeks in an initial treatment period; patients who did not show an improvement in INCAT disability score of ≥1 point received the alternate treatment in a cross-over treatment period.…”

Section: Immunomodulation With Intravenous Immunoglobulins (Ivig)mentioning

confidence: 99%

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Melzer

Meuth

2014

Clin Exp Immunol

View full text Add to dashboard Cite

OTHER ARTICLES PUBLISHED IN THIS SERIESParaneoplastic neurological syndromes. Clinical and Experimental Immunology 2014, 175: 336-48. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical and Experimental Immunology 2014, 175: 349-58. Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology 2014, 175: 373-84 SummaryMultiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represent chronic, autoimmune demyelinating disorders of the central and peripheral nervous system. Although both disorders share some fundamental pathogenic elements, treatments do not provide uniform effects across both disorders. We aim at providing an overview of current and future disease-modifying strategies in these disorders to demonstrate communalities and distinctions.

show abstract

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

Cited by 585 publications

References 23 publications

Immunotherapy in Peripheral Neuropathies

Immunotherapy in Peripheral Neuropathies

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Contact Info

Product

Resources

About